---
layout: default
title: Pidotimod
parent: 僅模型預測 (L5)
nav_order: 662
evidence_level: L5
indication_count: 10
---

# Pidotimod
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pidotimod: From Unspecified Original Indication to Osteoarthritis

## One-Sentence Summary

The evidence pack does not record Pidotimod's original approved indication or mechanism of action (both flagged as data gaps). The TxGNN model predicts potential efficacy for **Osteoarthritis**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the pack's own mechanistic review flags it as likely graph noise rather than a biologically grounded signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (no licenses or indication text available) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.56% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for Pidotimod is not available in this evidence pack (marked as a High-severity data gap), and no original indication is on record. Without this information, an independent mechanistic case for repurposing cannot be constructed from the pack alone.

The evidence pack does include the model's own mechanistic assessment, and it is not favorable: for osteoarthritis, the note states that OA is primarily driven by cartilage degeneration and low-grade inflammation, which has no direct connection to Pidotimod's known immunostimulatory activity, and that the high TxGNN score likely reflects an indirect link through inflammation/immune nodes in the knowledge graph rather than genuine mechanistic relevance.

Notably, several of the other top-10 predicted indications in this pack (rheumatoid arthritis, gout) are flagged by the same rationale as mechanistically *contradictory* — Pidotimod is an immune stimulant, whereas these conditions require immune suppression or anti-inflammatory action. This pattern across the candidate list reinforces that the current top prediction should be treated as a hypothesis-generating signal only, not a mechanistically supported lead.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Pidotimod is not marketed in Taiwan/India per this evidence pack (0 registrations, no license records available), so no authorization table can be produced.

---

## Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are available in this evidence pack — TFDA warning/contraindication data is flagged as a **Blocking** data gap, and the DDI database query returned no results.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The prediction is TxGNN-model-only (L5), with zero clinical trials or literature support, and the pack's own mechanistic review does not find a plausible biological rationale for osteoarthritis.
- A Blocking data gap on TFDA warnings/contraindications means safety cannot even complete the S1 initial screen, and the drug is not currently marketed in Taiwan/India.

**To proceed, the following is needed:**
- TFDA/regulatory label data (warnings, contraindications) to clear the Blocking data gap
- Confirmed mechanism of action and original approved indication(s) for Pidotimod
- Preclinical or observational evidence specifically linking Pidotimod to osteoarthritis before considering trial-stage investment
- Re-screening of lower-ranked candidates (e.g., rheumatoid arthritis, gout) is not recommended given documented mechanistic contradiction with Pidotimod's immunostimulatory action
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

